Home › Companies › THERAVANCE BIOPHARMA INC. › 2023-2024
Compiled from SEC Form N-PX filings and THERAVANCE BIOPHARMA INC.’s Form 8-K, filed 2024-05-09 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore THERAVANCE BIOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are THERAVANCE BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Eran Broshy | 35,316,310 | 223,797 | 635 | -- | 3,952,947 | Majority: yes |
| Elect Director: James Kelly | 35,265,676 | 274,631 | 435 | -- | 3,952,947 | Majority: yes |
| Elect Director: Laurie Smaldone Alsup | 35,290,841 | 240,365 | 9,536 | -- | 3,952,947 | Majority: yes |
| Elect Director: Number of Shares Voted | 39,257,982 | 228,078 | 7,629 | -- | -- | Majority: yes |
| Elect Director: Number of Shares Voted | 35,205,714 | 332,345 | 2,683 | -- | 3,952,947 | Majority: yes |
Source: THERAVANCE BIOPHARMA INC., Form 8-K, filed with the SEC on 2024-05-09 — read the filing on EDGAR.
Each item below shows how the 147 asset managers that disclosed a THERAVANCE BIOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of THERAVANCE BIOPHARMA INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
99.3% fund support · no official result
The 145 asset managers below cast 99.3% of the shares they voted on this item FOR (34,606,975 for, 217,766 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Baupost | 6,594,126 | 0 | 0 | 0 | For |
| Madison Avenue Partners, LP | 6,281,141 | 0 | 0 | 0 | For |
| Weiss Asset Management LP | 5,593,147 | 0 | 0 | 0 | For |
| Newtyn Management, LLC | 3,245,996 | 0 | 0 | 0 | For |
| Irenic Capital Management LP | 2,333,447 | 0 | 0 | 0 | For |
| BlackRock | 2,173,654 | 0 | 0 | 0 | For |
| Vanguard | 1,415,054 | 0 | 0 | 0 | For |
| Park West Asset Management LLC | 1,101,711 | 0 | 0 | 0 | For |
| State Street | 837,223 | 5,822 | 0 | 0 | For |
| Camber Capital Management LP | 815,798 | 0 | 0 | 0 | For |
| DE Shaw | 500,879 | 0 | 0 | 0 | For |
| Charles Schwab | 443,810 | 0 | 0 | 0 | For |
| Northern Trust | 324,620 | 1,234 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 314,374 | 0 | 0 | 0 | For |
| Wellington | 303,720 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Chescapmanager LLC | 201,365 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 127,084 | 0 | 0 | 0 | For |
| Goldman Sachs | 114,650 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 109,987 | 0 | 0 | 0 | For |
| SEI | 97,434 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 84,061 | 0 | 0 | 0 | For |
| Equitable | 83,089 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 79,716 | 0 | 0 | Against |
| Invesco | 74,005 | 0 | 0 | 0 | For |
Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
THERAVANCE BIOPHARMA INC.’s own tally for this item (“Elect Director: Eran Broshy”): 35,316,310 for, 223,797 against, per its Form 8-K filed 2024-05-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,566,000 outstanding shares: 73% for, 0.5% against (73% of the company cast a for/against vote).
The 45 asset managers below cast 100% of the shares they voted on this item FOR (3,812,622 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,368,681 | 0 | 0 | 0 | For |
| BlackRock | 1,040,354 | 0 | 0 | 0 | For |
| Charles Schwab | 221,905 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 109,987 | 0 | 0 | 0 | For |
| Equitable | 83,089 | 0 | 0 | 0 | For |
| State Street | 74,890 | 0 | 0 | 0 | For |
| Nationwide | 69,959 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 65,948 | 0 | 0 | 0 | For |
| Royce | 59,009 | 0 | 0 | 0 | For |
| SEI | 47,617 | 0 | 0 | 0 | For |
| Fidelity | 47,042 | 0 | 0 | 0 | For |
| Northern Trust | 46,024 | 0 | 0 | 0 | For |
| Global X | 43,905 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,700 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 34,607 | 0 | 0 | 0 | For |
| Invesco | 26,869 | 0 | 0 | 0 | For |
| Dimensional | 24,015 | 0 | 0 | 0 | For |
| American Century | 21,861 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,293 | 0 | 0 | 0 | For |
| Pacific Life | 20,460 | 0 | 0 | 0 | For |
| John Hancock | 20,262 | 0 | 0 | 0 | For |
| New York Life | 14,097 | 0 | 0 | 0 | For |
| Voya | 14,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 12,667 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
THERAVANCE BIOPHARMA INC.’s own tally for this item (“Elect Director: James Kelly”): 35,265,676 for, 274,631 against, per its Form 8-K filed 2024-05-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,566,000 outstanding shares: 73% for, 0.6% against (73% of the company cast a for/against vote).
The 45 asset managers below cast 99.8% of the shares they voted on this item FOR (3,805,468 for, 7,154 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,368,681 | 0 | 0 | 0 | For |
| BlackRock | 1,040,354 | 0 | 0 | 0 | For |
| Charles Schwab | 221,905 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 109,987 | 0 | 0 | 0 | For |
| Equitable | 83,089 | 0 | 0 | 0 | For |
| State Street | 74,890 | 0 | 0 | 0 | For |
| Nationwide | 68,888 | 1,071 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 65,948 | 0 | 0 | 0 | For |
| Royce | 59,009 | 0 | 0 | 0 | For |
| SEI | 47,617 | 0 | 0 | 0 | For |
| Fidelity | 47,042 | 0 | 0 | 0 | For |
| Northern Trust | 46,024 | 0 | 0 | 0 | For |
| Global X | 43,905 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,700 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 34,607 | 0 | 0 | 0 | For |
| Invesco | 26,869 | 0 | 0 | 0 | For |
| Dimensional | 24,015 | 0 | 0 | 0 | For |
| American Century | 21,861 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,293 | 0 | 0 | 0 | For |
| Pacific Life | 20,460 | 0 | 0 | 0 | For |
| John Hancock | 20,262 | 0 | 0 | 0 | For |
| New York Life | 14,097 | 0 | 0 | 0 | For |
| Voya | 14,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 12,667 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
THERAVANCE BIOPHARMA INC.’s own tally for this item (“Elect Director: Laurie Smaldone Alsup”): 35,290,841 for, 240,365 against, per its Form 8-K filed 2024-05-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,566,000 outstanding shares: 73% for, 0.5% against (73% of the company cast a for/against vote).
The 45 asset managers below cast 99.8% of the shares they voted on this item FOR (3,805,468 for, 7,154 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,368,681 | 0 | 0 | 0 | For |
| BlackRock | 1,040,354 | 0 | 0 | 0 | For |
| Charles Schwab | 221,905 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 109,987 | 0 | 0 | 0 | For |
| Equitable | 83,089 | 0 | 0 | 0 | For |
| State Street | 74,890 | 0 | 0 | 0 | For |
| Nationwide | 68,888 | 1,071 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 65,948 | 0 | 0 | 0 | For |
| Royce | 59,009 | 0 | 0 | 0 | For |
| SEI | 47,617 | 0 | 0 | 0 | For |
| Fidelity | 47,042 | 0 | 0 | 0 | For |
| Northern Trust | 46,024 | 0 | 0 | 0 | For |
| Global X | 43,905 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,700 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 34,607 | 0 | 0 | 0 | For |
| Invesco | 26,869 | 0 | 0 | 0 | For |
| Dimensional | 24,015 | 0 | 0 | 0 | For |
| American Century | 21,861 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,293 | 0 | 0 | 0 | For |
| Pacific Life | 20,460 | 0 | 0 | 0 | For |
| John Hancock | 20,262 | 0 | 0 | 0 | For |
| New York Life | 14,097 | 0 | 0 | 0 | For |
| Voya | 14,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 12,667 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 45 asset managers below cast 100% of the shares they voted on this item FOR (3,812,622 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,368,681 | 0 | 0 | 0 | For |
| BlackRock | 1,040,354 | 0 | 0 | 0 | For |
| Charles Schwab | 221,905 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 208,783 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 109,987 | 0 | 0 | 0 | For |
| Equitable | 83,089 | 0 | 0 | 0 | For |
| State Street | 74,890 | 0 | 0 | 0 | For |
| Nationwide | 69,959 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 65,948 | 0 | 0 | 0 | For |
| Royce | 59,009 | 0 | 0 | 0 | For |
| SEI | 47,617 | 0 | 0 | 0 | For |
| Fidelity | 47,042 | 0 | 0 | 0 | For |
| Northern Trust | 46,024 | 0 | 0 | 0 | For |
| Global X | 43,905 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,700 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 34,607 | 0 | 0 | 0 | For |
| Invesco | 26,869 | 0 | 0 | 0 | For |
| Dimensional | 24,015 | 0 | 0 | 0 | For |
| American Century | 21,861 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,293 | 0 | 0 | 0 | For |
| Pacific Life | 20,460 | 0 | 0 | 0 | For |
| John Hancock | 20,262 | 0 | 0 | 0 | For |
| New York Life | 14,097 | 0 | 0 | 0 | For |
| Voya | 14,034 | 0 | 0 | 0 | For |
| Goldman Sachs | 12,667 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Ranked by the number of THERAVANCE BIOPHARMA INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 48,566,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Baupost | 13.58% |
| 2 | Madison Avenue Partners, LP | 12.93% |
| 3 | Weiss Asset Management LP | 11.52% |
| 4 | Newtyn Management, LLC | 6.68% |
| 5 | Irenic Capital Management LP | 4.80% |
| 6 | BlackRock | 4.48% |
| 7 | Vanguard | 2.91% |
| 8 | Park West Asset Management LLC | 2.27% |
| 9 | State Street | 1.74% |
| 10 | Camber Capital Management LP | 1.68% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Weiss Asset Management LP | 15.35% | DEF14A |
| The Baupost Group, L.L.C | 15.28% | DEF14A |
| Madison Avenue Partners, LP | 14.44% | DEF14A |
| Odre 2005 SL Pineta, 18B, Polígono Valdeconsejo, Nave 5 CP50410, Cuarte de Huerva (Zaragoz | 8.46% | DEF14A |
| BlackRock | 8.38% | 13F |
| Irenic Capital Management LP | 5.68% | DEF14A |
| Vanguard Group | 4.55% | 13F |
| Rick E Winningham | 3.94% | DEF14A |
| State Street | 2.82% | 13F |
| D.E. Shaw | 1.61% | 13F |
Percentages above are of 48,566,000 shares outstanding, as reported by THERAVANCE BIOPHARMA INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from THERAVANCE BIOPHARMA INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At THERAVANCE BIOPHARMA INC.'s shareholder meeting held 2024-05-08, in the 2023-2024 proxy season, 147 asset managers reported how they voted in their SEC Form N-PX filings, covering 875 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. THERAVANCE BIOPHARMA INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To vote on a non-binding advisory resolution regarding the compensation of Theravance Biopharma… — the reporting funds cast 99.3% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
THERAVANCE BIOPHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.